Century Therapeutics (NASDAQ:IPSC) Releases Earnings Results, Misses Expectations By $0.22 EPS

Century Therapeutics (NASDAQ:IPSC – Get Rating) released its earnings results on Monday. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.22), MarketWatch Earnings reports.

Shares of IPSC traded up $0.79 during midday trading on Tuesday, hitting $8.86. 78,035 shares of the company traded hands, compared to its average volume of 101,426. Century Therapeutics has a 52 week low of $7.32 and a 52 week high of $32.90. The company has a quick ratio of 14.57, a current ratio of 14.57 and a debt-to-equity ratio of 0.03. The firm has a 50 day moving average of $11.78 and a 200-day moving average of $14.27.

Several institutional investors have recently added to or reduced their stakes in IPSC. Royal Bank of Canada purchased a new stake in Century Therapeutics in the 3rd quarter worth about $35,000. Citigroup Inc. increased its stake in shares of Century Therapeutics by 254.6% during the fourth quarter. Citigroup Inc. now owns 4,734 shares of the company’s stock valued at $75,000 after buying an additional 3,399 shares during the period. American International Group Inc. raised its holdings in shares of Century Therapeutics by 37.1% in the first quarter. American International Group Inc. now owns 8,604 shares of the company’s stock valued at $108,000 after acquiring an additional 2,328 shares in the last quarter. MetLife Investment Management LLC purchased a new stake in shares of Century Therapeutics in the 1st quarter worth approximately $153,000. Finally, California State Teachers Retirement System purchased a new stake in shares of Century Therapeutics during the 3rd quarter worth $161,000. Hedge funds and other institutional investors own 57.50% of the company’s stock.

A number of analysts have weighed in on IPSC shares. Zacks Investment Research upgraded shares of Century Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, May 3rd. William Blair started coverage on shares of Century Therapeutics in a research note on Thursday, May 12th. They set a “market perform” rating on the stock. SVB Leerink reissued a “buy” rating and set a $32.00 price objective on shares of Century Therapeutics in a report on Friday, March 18th. Finally, Piper Sandler dropped their target price on shares of Century Therapeutics from $38.00 to $22.00 in a report on Monday. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $32.00.

Century Therapeutics Company Profile (Get Rating)

Century Therapeutics, Inc, a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma.

Recommended Stories